Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Poster session 12

880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma

Date

21 Oct 2023

Session

Poster session 12

Topics

Clinical Research

Tumour Site

Head and Neck Cancers

Presenters

Nora Würdemann

Citation

Annals of Oncology (2023) 34 (suppl_2): S554-S593. 10.1016/S0923-7534(23)01938-5

Authors

N. Würdemann1, C. Alidousty2, O.G. Siefer3, C.U. Hübbers3, S. Silling4, D. Schafigh3, R. Bacher5, R. Büttner2, M. Dietlein5, U. Wieland6, A. Drzezga5, M. Schlamann7, A. Quaas8, C. Wittekindt9, I. Demers10, E. Speel10, S. Wagner11, J. George12, A. Schultheis13, J.P. Klussmann14

Author affiliations

  • 1 Department I Of Internal Medicine, University Hospital Cologne, 50924 - Köln/DE
  • 2 Department Of Pathology, University Hospital Cologne, 50924 - Köln/DE
  • 3 Department Of Otorhinolaryngology, Head And Neck Surgery, University Hospital Cologne, 50924 - Köln/DE
  • 4 Institute Of Virology, University Hospital Cologne, 50924 - Köln/DE
  • 5 Department Of Nuclear Medicine, University Hospital Cologne, 50924 - Köln/DE
  • 6 Department Of Virology, University Hospital Cologne, 50924 - Köln/DE
  • 7 Institute Of Diagnostic And Interventional Radiology, University Hospital Cologne, 50924 - Köln/DE
  • 8 Department Of Pathology, Universitätsklinikum Köln (AöR), 50937 - Köln/DE
  • 9 Department Of Otorhinolaryngology, Head And Neck Surgery, Medizinische Klinik Mitte Klinikum Dortmund GmbH, 44137 - Dortmund/DE
  • 10 Institute Of Pathology, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 11 Department Of Otorhinolaryngology, Head And Neck Surgery, University of Giessen, 35392 - Giessen/DE
  • 12 Department Of Otorhinolaryngology, Head And Neck Surgery, University Hospital of Cologne, 50937 - Cologne/DE
  • 13 Institute Of Pathology, University Hospital Cologne, 50924 - Köln/DE
  • 14 Department Of Otorhinolaryngology, Head And Neck Surgery, Universitätsklinikum Köln (AöR), 50937 - Köln/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 880P

Background

Globally the incidences of oropharyngeal squamous cell carcinoma (OPSCC), especially those associated with high-risk human papillomavirus are rising. Although patients with HPV-positive OPSCC present with better survival, up to 25% develop recurrent disease. Biomarkers to monitor therapy response, minimal residual disease and tumor burden during follow-up are urgently needed. The detection of cell-free (cf)HPV-DNA in blood plasma offers the opportunity for minimally invasive disease monitoring and early recurrence detection.

Methods

We examined 34 patients with HPV-related OPSCC and 21 controls (healthy donors and HPV-negative OPSCC patients) to investigate cfHPV16-DNA status prior to and during therapy as well as throughout follow-up. qPCR and ddPCR were applied to quantify the concentration of cfHPV16-DNA in plasma, using the viral gene E6 as a target.

Results

No cfHPV16-DNA or <10 copies per ml plasma were detected in healthy donors or HPV-negative OPSCC patients. Plasma samples from patients with HPV-positive OPSCC collected prior to treatment. At the cut-off of 10 copies/ml plasma, ddPCR showed 79% sensitivity, 80% specificity, 70% NPV, and 90% PPV, whereas qPCR showed 73% sensitivity, 80% specificity, 60% NPV, 90% PPV. Patients without clinical evidence of recurrence had significantly lower cfHPV16-DNA concentrations after therapy, whereas increase of copy number was correlated to recurrent disease.

Conclusions

Our results demonstrate that ddPCR is a more sensitive method compared to qPCR for detection of cfHPV16-DNA in plasma of patients with HPV16-positive OPSCC. cfHPV16-DNA correlated with tumor burden and therefore presents a promising diagnostic tool. Nevertheless, prospective studies with expanded patient cohorts are necessary to investigate the kinetics of cfHPV16-DNA in relation to therapy response and the development of recurrent and metastatic disease.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Dr. Nora Würdemann.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.